RAPT Therapeutics Inc (RAPT)

(10% Negative) RAPT Therapeutics Inc (RAPT) Announces Delay in opportunity Trials for ozureprubart Due to Patient Enrollment Issues, Regulatory Process, Safety Review, Efficacy Assessment